Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$13.92 -0.46 (-3.20%)
As of: Sep 4, 2026 · 3:20 PM EDT

Monte Rosa Therapeutics (GLUE) Assets Growth (3y) (2023 - 2026)

Analysis

Monte Rosa Therapeutics (GLUE) Assets Growth (3y) (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn -
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn -
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn
10 Monte Rosa Therapeutics 1.41 Bn 781.72 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 35.37%
Mar 31, 2026 33.57%
Dec 31, 2025 9.43%
Sep 30, 2025 8.74%
Jun 30, 2025 -0.50%
Mar 31, 2025 4.35%
Dec 31, 2024 6.20%
Sep 30, 2024 -6.39%
Jun 30, 2024 -2.30%
Dec 31, 2023 83.23%